News

$70 million raised to accelerate development of US-based Suki’s AI technology

US-based AI technology provider Suki has announced that it has raised $70 million in new funding for its mission to “make healthcare technology invisible and assistive with an AI platform that powers the industry”.

The new funding brings the total raised to $165 million, which Suki says will help boost its investment in commercial initiatives, accelerate its product development, and expand its leadership team.

Punit Soni, CEO and founder of Suki, said that the company is “in a new phase of growth”, highlighting relationships with strategic partners including MedStar Health as “fundamental” in helping to build “essential capabilities” such as EHR integration.

At MedStar Health health system, Suki’s assistant is available to clinicians across specialities including primary care, cardiology and gastroenterology, where it is integrated with the system’s Oracle Cerner EHR.

At present, the company’s offerings include an assistant that uses AI and voice technology to help clinicians “save time on tedious administrative tasks” through functionality such as ambient note generation and answering clinical questions using data from EHRs.

In other news on funding, May, a French app designed for future parents and offering medical messaging, pregnancy support and a range of health tools designed to “simplify your daily life”, has raised €7 million in funding to support expansion plans.

And in AI, the University of Illinois Chicago is set to lead a project in collaboration with the University of Iowa, University of Missouri, Loyola University, Microsoft and Tackle AI which will see artificial intelligence utilised to unify data from a range of health professions.

Collaboration is also underway in Finland and the US, where an agreement between Orion Corporation, a Finnish pharmaceutical company, and Aitia, an AI-enabled biotech company based in Massachusetts, will see the creation of “Gemini Digital Twins” to combine with Orion’s pre-clinical and clinical data.

Explore HTN Interviews